APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
A phase 1/2 trial of APG-115 in neuroblastoma, run by Ascentage Pharma Group Inc., now recruiting.
Overview
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors is a phase 1/2 interventional study registered as NCT05701306 by Ascentage Pharma Group Inc., with 100 participants planned, started 2023-02-28 and due to reach its primary completion in 2027-06-01. Interventions recorded: APG-115 and APG-2575.
Similar pages
not linked directly; found by shared links- TrialStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Shares Ascentage Pharma and the tag pipeline.
- TrialA Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Shares Ascentage Pharma and the tag pipeline.
- TrialOpen-Label Study of 18F-mFBG for Imaging Neuroblastoma
Shares Neuroblastoma (paediatric) and the tag pipeline.
- TrialA Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Shares Ascentage Pharma and the tag pipeline.
- TrialAPG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Shares Ascentage Pharma and the tag pipeline.
- TrialStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Shares Ascentage Pharma and the tag pipeline.
- TrialDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Shares Neuroblastoma (paediatric) and the tag pipeline.